RxDoctor Payments Data

Viachaslau Kazelka, MD

Family Medicine · Eau Claire, WINPI 1518279330

Payments from drug & device makers

$823in general payments, 2019–2025

Across 12 payments — averaging $68.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$210
  • Lundbeck LLC$151
  • GSK$140
  • Phathom Pharmaceuticals, Inc.$125
  • Novo Nordisk$116
  • Pfizer$52
  • plus $28 from 1 others

What the payments were for

  • Food & beverage$823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$823 in reported general payments places this provider in the 85th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$71,110
Medicare patients
215
Services billed
4,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$100,484
TrulicityDulaglutide67$67,741
EliquisApixaban72$66,804
JardianceEmpagliflozin55$65,776
XareltoRivaroxaban40$26,781
RybelsusSemaglutide11$21,436
FarxigaDapagliflozin Propanediol12$13,741
LyricaPregabalin12$12,262
MyrbetriqMirabegron23$12,115
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$11,576
Incruse ElliptaUmeclidinium Bromide21$11,517
Semglee (Yfgn) PenInsulin Glargine-Yfgn23$10,056
Emgality PenGalcanezumab-Gnlm13$9,454
Aimovig AutoinjectorErenumab-Aooe12$8,883
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$8,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$116$121,920104 claims
PfizerEliquis, Lyrica$52$79,06684 claims
Johnson & JohnsonXarelto$28$26,78140 claims
AstraZenecaFarxiga$210$13,74112 claims
GSKIncruse Ellipta$140$11,51721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Eau Claire

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →